



• Pharmacogenomics is the study and application of the genetic determinants of
drug response.
• To date, clinical guidelines providing treatment recommendations are available
for ~70 drugs whose response is associated with variation in one or more genes.
• However importantly, this variation is almost exclusively limited to common
variants (minor allele frequency (MAF) ≥ 1%).
• The world-leading UK 100,000 Genomes Project1 offers the opportunity to
further investigate variation in genes involved in drug pharmacokinetics (PK) or
pharmacodynamics (PD) – hereafter termed ‘pharmacogenes’.
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• The aim of this study was to comprehensively identify and describe variation in
pharmacogenes observed within the 100,000 Genomes Project, and to estimate
the proportion of functional genomic variation attributable to rare variation.
• The UK 100,000 Genomes Project recruited patients with a rare disease and their 
unaffected relatives, and patients with cancer, between 2014 and 20181.  
• DNA from all participants underwent whole genome sequencing, which was 
completed in December 2018.   
• Single nucleotide variants (SNVs) and indels from pharmacogenes were extracted 
from all quality-controlled germline whole genome sequence data available on 1st
February 2019 – this included both rare disease & cancer participants.  
• Cellbase variant annotations were used, whilst SIFT and Polyphen2 algorithms were 
used to predict in silico the functional consequences of nonsynonymous SNVs.  
• Functional variants were defined as those predicted to have a high or moderate 
impact on gene function according to the Sequence Ontology consequence 
hierarchy; missense variants were only considered functional if they were predicted 
deleterious/at least possible damaging by SIFT/Polyphen2.  
• Data analysis was undertaken within the Genomics England research environment, 
following project approval by Genomics England.
Results
• In total, 195 pharmacogenes from 60,221 individuals were analysed (Figure 1).
• 2,164,677 variants were identified: 1,978,194 SNVs (91.4%) & 186,483 indels (8.6%).  
• Only 2.8% of identified variants were common; 94.0% of identified variants were 
very rare (MAF < 0.1%), and 3.2% rare (MAF < 1% but ≥ 0.1%) (Figure 2).  
• The majority of identified variants were intronic and classed as modifiers; 3% of 
identified variants were predicted to have a high (e.g. frameshift), moderate (e.g. 
missense) or low (e.g. synonymous) impact on gene function (Figure 3).  
• Of this 3% of variants, 58% were missense, 28% synonymous, and the majority of 
the remainder were high impact variants (Figure 3).  
• Importantly, the mean number of distinct high impact variants identified per gene 
varied across gene classes, ranging from 24.2 variants in transporter genes to 4.8 
variants in genes related to neuropsychiatric drug targets (Figure 4, Table 1).  
• The fraction of predicted functional variation attributable to rare variants differed 
extensively between genes and, in over half of analysed pharmacogenes, rare 
variants accounted for all identified functional variation (Figure 5).  
• Overall on average, each participant carried 37 putatively functional variants within 
the analysed gene set, of which 4 variants (10.9%) were rare.  
• This study found that the majority of variants in pharmacogenes are very rare.
• The prevalence of high impact variants differ between gene classes, plausibly 
reflecting the extent of evolutionary tolerance to perturbed gene function. 
• The overall proportion of putative functional variation attributable to rare 
variants was modest but not insignificant, given that ~80% of all adverse drug 
reactions are ‘type A’ reactions related to excessive on-target drug action where 
variation in drug PK and on-target PD are key.  
• Importantly, the impact of rare variation on drug response is predicted to differ 
notably between drugs, dependent on the extent of rare variation in genes 
relevant to each drug.  
• This study will be extended to determine the extent of variation in this gene set 
within the somatic genome.
Figure 1. Study overview
Table 1. Variation in the number of high impact variants by gene class
Figure 5. Functional variation attributable to common & rare variants in select gene classes
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Figure 2. Overall frequency 








Figure 3. An overview of 
variant types
Figure 4. Genomic variation 
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